LCM
TARS icon

Laurion Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Laurion Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$3.63M – 747
2024
Q1 		$3.63M Buy
+100,000
New +$2.94M 0.03% 287

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Laurion Capital Management's TARS Position: Q2 2024 in Review

Laurion Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2024, closing a stake of 100,000 shares — an estimated $3.63M sold.

Laurion Capital Management first reported a position in TARS in Q1 2024 and held it in 1 quarter. The position peaked at $3.63M in Q1 2024. 148 funds tracked by Wall St. Rank hold TARS as of Q2 2024.

  • Laurion Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 100,000 Tarsus Pharmaceuticals shares in Q2 2024, an estimated $3.63M.
  • Laurion Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Laurion Capital Management's Tarsus Pharmaceuticals position peaked at $3.63M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.